The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

Pliant Therapeutics Inc. (PLRX) suffered a major blow on Friday, with its shares tumbling nearly 35% in regular trading and plunging ...